PE20221009A1 - Sintesis de un inhibidor de calicreina plasmatica a escala de proceso - Google Patents

Sintesis de un inhibidor de calicreina plasmatica a escala de proceso

Info

Publication number
PE20221009A1
PE20221009A1 PE2022000188A PE2022000188A PE20221009A1 PE 20221009 A1 PE20221009 A1 PE 20221009A1 PE 2022000188 A PE2022000188 A PE 2022000188A PE 2022000188 A PE2022000188 A PE 2022000188A PE 20221009 A1 PE20221009 A1 PE 20221009A1
Authority
PE
Peru
Prior art keywords
kallicerein
inhibitor
plasma
synthesis
salt
Prior art date
Application number
PE2022000188A
Other languages
English (en)
Spanish (es)
Inventor
Yahya El-Kattan
Yarlagadda S Babu
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of PE20221009A1 publication Critical patent/PE20221009A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00Preparation of carboxylic acid nitriles
    • C07C253/30Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
PE2022000188A 2019-08-06 2020-08-05 Sintesis de un inhibidor de calicreina plasmatica a escala de proceso PE20221009A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962883396P 2019-08-06 2019-08-06
PCT/US2020/044921 WO2021026182A1 (en) 2019-08-06 2020-08-05 Process-scale synthesis of a plasma kallikrein inhibitor

Publications (1)

Publication Number Publication Date
PE20221009A1 true PE20221009A1 (es) 2022-06-15

Family

ID=74504082

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000188A PE20221009A1 (es) 2019-08-06 2020-08-05 Sintesis de un inhibidor de calicreina plasmatica a escala de proceso

Country Status (26)

Country Link
US (1) US12503443B2 (https=)
EP (1) EP4010320A4 (https=)
JP (1) JP7626751B2 (https=)
KR (1) KR102928815B1 (https=)
CN (1) CN114206839B (https=)
AR (1) AR119617A1 (https=)
AU (1) AU2020324422B2 (https=)
BR (1) BR112022002060A2 (https=)
CA (1) CA3149176A1 (https=)
CL (2) CL2022000264A1 (https=)
CO (1) CO2022002392A2 (https=)
CR (1) CR20220092A (https=)
DO (1) DOP2022000027A (https=)
EC (1) ECSP22016209A (https=)
GE (2) GEAP202515893A (https=)
IL (1) IL290113B2 (https=)
JO (1) JOP20220021A1 (https=)
MX (1) MX2022001608A (https=)
PE (1) PE20221009A1 (https=)
PH (1) PH12022550221A1 (https=)
PY (1) PY2042865A (https=)
TN (1) TN2022000028A1 (https=)
TW (1) TWI881995B (https=)
UA (1) UA130182C2 (https=)
UY (1) UY38826A (https=)
WO (1) WO2021026182A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102736869B1 (ko) 2014-03-07 2024-12-02 바이오크리스트파마슈티컬즈,인코포레이티드 인간 혈장 칼리크레인 저해제
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
CN114206839B (zh) 2019-08-06 2025-03-07 拜奥克里斯特制药公司 血浆激肽释放酶抑制剂的生产规模合成
CN116375648A (zh) * 2023-03-22 2023-07-04 苏州农平科技发展有限公司 贝罗司他中间体的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
DE69110787T2 (de) 1990-02-28 1996-04-04 Medtronic, Inc., Minneapolis, Minn. Intraluminale prothese mit wirkstoffeluierung.
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
DE60034447T2 (de) 2000-08-11 2008-02-14 Wilex Ag Nicht-kovalente Urokinase-und Angiogenese-Inhibitoren
US7038057B2 (en) * 2001-08-13 2006-05-02 E.I. Du Pont De Nemours And Company Substituted 1H-dihydropyrazoles, their preparation and use
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
MX2011006319A (es) * 2008-12-18 2011-06-24 Bayer Cropscience Ag Amidas del acido antranilico sustituidas con tetrazol como plaguicidas.
CN102464701B (zh) 2010-11-08 2015-10-21 上海医药工业研究院 一类新型化合物、其制备方法及用途
EP2909181B1 (en) 2012-10-16 2017-08-09 Tolero Pharmaceuticals, Inc. Pkm2 modulators and methods for their use
KR102736869B1 (ko) 2014-03-07 2024-12-02 바이오크리스트파마슈티컬즈,인코포레이티드 인간 혈장 칼리크레인 저해제
CN114206839B (zh) 2019-08-06 2025-03-07 拜奥克里斯特制药公司 血浆激肽释放酶抑制剂的生产规模合成

Also Published As

Publication number Publication date
IL290113B1 (en) 2025-04-01
GEAP202515893A (en) 2025-02-25
TN2022000028A1 (en) 2023-10-09
CR20220092A (es) 2022-06-03
BR112022002060A2 (pt) 2022-06-07
AR119617A1 (es) 2021-12-29
JP7626751B2 (ja) 2025-02-04
AU2020324422A1 (en) 2022-03-17
US12503443B2 (en) 2025-12-23
UY38826A (es) 2021-02-26
WO2021026182A1 (en) 2021-02-11
GEP20257777B (en) 2025-07-10
JP2022543419A (ja) 2022-10-12
CA3149176A1 (en) 2021-02-11
UA130182C2 (uk) 2025-12-10
PH12022550221A1 (en) 2022-12-19
TW202120481A (zh) 2021-06-01
EP4010320A4 (en) 2023-08-16
CL2023000942A1 (es) 2023-11-24
MX2022001608A (es) 2022-03-11
CN114206839A (zh) 2022-03-18
KR102928815B1 (ko) 2026-02-19
JOP20220021A1 (ar) 2023-01-30
DOP2022000027A (es) 2022-05-31
US20220289683A1 (en) 2022-09-15
CO2022002392A2 (es) 2022-04-08
IL290113A (en) 2022-03-01
ECSP22016209A (es) 2022-06-30
EP4010320A1 (en) 2022-06-15
IL290113B2 (en) 2025-08-01
CN114206839B (zh) 2025-03-07
CL2022000264A1 (es) 2022-10-21
PY2042865A (es) 2021-05-05
AU2020324422B2 (en) 2026-02-26
TWI881995B (zh) 2025-05-01
KR20220044276A (ko) 2022-04-07

Similar Documents

Publication Publication Date Title
PE20221009A1 (es) Sintesis de un inhibidor de calicreina plasmatica a escala de proceso
CL2020000407A1 (es) Proceso para preparar compuesto inhibidor de bet. (solicitud divisional 201803702).
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
CL2020001752A1 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa.
MX388474B (es) Composiciones que contienen tucaresol o sus análogos.
ECSP20035222A (es) Derivado de amino-fluoropiperidina como inhibidor de quinasa
MX2018000412A (es) Moduladores de diaciglicerol aciltransferasa 2 (dgat2).
AR111304A1 (es) Métodos para sintetizar un inhibidor de mcl-1
JOP20210050A1 (ar) معدلات تعبير pnpla3
MX2016006199A (es) Inhibidores de replicacion del virus de influenza.
CO2021008816A2 (es) Moduladores de trex1
CL2019002574A1 (es) Moduladores de la expresión de pcsk9.
AR105967A1 (es) Sales de un inhibidor de pim quinasa
MX2019010642A (es) Inhibidores de cinasa activada por mitogeno 2 (mk2), sintesis de los mismos, e intermediarios de los mismos.
MX2021007245A (es) Microorganismos para la produccion de putrescina u ornitina y procedimiento para la produccion de putrescina u ornitina usando los mismos.
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
CO2017003969A2 (es) Derivado de isoxazol como inhibidor de isocitrato deshidrogenasa 1 mutante
CL2018002466A1 (es) Proceso mejorado para la elaboración de un tablero aglomerado
SV2018005702A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
CO2021000087A2 (es) Combinación de factor vii y de un anticuerpo biespecífico dirigido contra los factores ix y x
NI201800065A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento de cáncer
CY1125096T1 (el) Χρηση μιας ενωσης για την προστασια φυτων μεσω συγκλεισης των στοματων και μεθοδος για την προστασια φυτων μεσω συγκλεισης στοματων που περιλαμβανει την εφαρμογη της εν λογω ενωσης στα φυτα
CO2019007836A2 (es) Derivados de pirrolotriazina como inhibidor de cinasas
MX2016015106A (es) Derivados de dipicolilamina y sus usos farmaceuticos.